Compare DexCom, Inc. (DXCM) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MGM Resorts International — how do they compare? DexCom, Inc. trades at $77.8 (market cap $28.06B), while MGM Resorts International trades at $46.49 (market cap $11.98B). The key difference: DexCom, Inc. is far larger — about 2.3× MGM Resorts International's market cap, and MGM Resorts International pays a 0.03% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MGM | |
|---|---|---|
Market Cap | $28.06B | $11.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $50.69 |
52-Week Low | $54.84 | $30.72 |
Enterprise Value | $27.03B | $41.03B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
MGM Resorts International (MGM) trades at $46.67, down 1.21% on the day, with a bullish technical signal and mixed earnings history. The company shows strong revenue growth from $13.1B in 2022 to $17.5B in 2025, though net income margin has compressed to 1.03%. Recent news indicates potential acquisition talks with Barry Diller's People Inc. at $48.30 per share, driving significant market attention and legal investigations regarding the offer price.
The stock presents a potential near-term catalyst from acquisition speculation, with a consensus price target of $48.93 offering modest upside. However, elevated P/E of 64.16 and declining profitability margins pose fundamental concerns. Risks include deal uncertainty, earnings volatility, and high debt levels, while analyst sentiment remains divided with 49% buy ratings versus 49% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
